Renin inhibition: A novel therapy for cardiovascular disease

Lin, Cherry; Frishman, William H.

doi:10.1016/s0002-8703(96)90190-8

Cited by 15 publications

(6 citation statements)

References 90 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the high specificity of human renin for human angiotensinogen was widely recognized as a significant limitation to the study of DRIs across species, 101 and the early in vivo assessment of human-specific DRIs has required the use of primates. 102 These animals are typically normotensive, and therefore, to detect effects on BP or changes in plasma renin activity (PRA) or total renin concentration, the use of a low sodium diet or diuretic pretreatment to activate the RAS is required. The first DRI to demonstrate BP lowering effects following oral administration was N2-[(phenylmethoxy)carbonyl]-L-arginyl-L-arginyl-L-prolyl-L-phenylalanyl-L-histidyl-(3S,4S)-4-amino-3-hydroxy-6-methylheptanoyl-L-isoleucyl-L-histidyl-N6-[(1,1-dimethylethoxy)carbonyl]-L-lysinemethyl ester (CGP29287).…”

Section: Preclinical Pharmacology Of Direct Renin Inhibitionmentioning

confidence: 99%

Direct Renin Inhibitors as a New Therapy for Hypertension

et al. 2010

View full text Add to dashboard Cite

Section: Preclinical Pharmacology Of Direct Renin Inhibitionmentioning

confidence: 99%

Direct Renin Inhibitors as a New Therapy for Hypertension

et al. 2010

View full text Add to dashboard Cite

“…14 Renin inhibition has potential for therapeutic benefits in conditions associated with high PRA. 11,15 Renin receptors have been identified in the human kidney. 16 In diabetes, the increase in prorenin exceeds substantially the increase in other diseases 17 and prorenin levels in type II diabetes correlate with severity of proteinuria and retinopathy.…”

Section: Potential For Direct Renin Inhibitionmentioning

confidence: 99%

Renin inhibition: the holy grail of renin–angiotensin system blockade?

McInnes

2007

J Hum Hypertens

View full text Add to dashboard Cite

“…The blockade induced by ACE inhibitors may be incomplete. In the cascade it is the renin-angiotensinogen interaction and not the ACE step that is rate limiting [63].…”

Section: Non-ace-dependent Pathwaysmentioning

confidence: 99%

Angiotensin receptor blockers in diabetic nephropathy

Price

Hollenberg

2001

Curr Diab Rep

View full text Add to dashboard Cite

Where shall we place angiotensin receptor blockers in the scheme of the prevention of diabetic nephropathy? Only the results of a large, randomized double-blind trial with a comparable and appropriate alternative would prove therapeutic efficacy. The results of several trials with angiotensin-converting enzyme (ACE) inhibitors have proven them to be the standard of care for diabetics and their kidneys. As reviewed in this article, the results of three large such clinical trials have recently been completed with angiotensin receptor blockers in patients with type 2 diabetes mellitus. Initial results appear favorable. However, whether angiotensin blockers have more to offer than ACE inhibitors is still speculative. The renin-angiotensin system plays an important role in the pathogenesis of diabetic nephropathy. Since alternative pathways to ACE have been uncovered in the formation of angiotensin II, inhibition at the final end point would provide favored blockade. Because angiotensin receptor blockers do provide this specific blockade, they offer far more promise than ACE inhibitors.

show abstract

Renin inhibition: A novel therapy for cardiovascular disease

Cited by 15 publications

References 90 publications

Direct Renin Inhibitors as a New Therapy for Hypertension

Direct Renin Inhibitors as a New Therapy for Hypertension

Renin inhibition: the holy grail of renin–angiotensin system blockade?

Angiotensin receptor blockers in diabetic nephropathy

Contact Info

Product

Resources

About